Adding an immune-boosting drug to standard cancer treatment for esophageal cancer

Plain-English translation of NCT04973306 on ClinicalTrials.gov ↗ · Source last updated June 2022 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether adding (an immune-boosting drug) to standard chemotherapy and radiation therapy can help treat advanced esophageal cancer more effectively. Right now, patients typically receive chemotherapy and radiation before surgery. Researchers want to see if adding this medication to the standard treatment plan leads to better results and helps more people survive longer.

Even with current chemotherapy and radiation treatment, many people with advanced esophageal cancer still experience cancer returning or spreading. This new treatment aims to help the body's immune system fight the cancer more effectively and improve survival rates.

Do you qualify?

You likely qualify if…

you have been diagnosed with squamous cell carcinoma of the esophagus at stage II or III
you are between 18 and 75 years old
you are in good enough overall health to tolerate intensive treatment and expected to live at least 12 months
you have adequate heart, lung, liver, and kidney function based on recent test results
you have not previously received chemotherapy, radiation, or other cancer treatments for this condition

You likely don't qualify if…

you have an autoimmune disease or a history of autoimmune conditions
you are currently taking steroids or immune-suppressing medications
you have a known allergy to antibody drugs or to chemotherapy drugs like Paclitaxel and Carboplatin
you have active HIV, hepatitis B, or hepatitis C infection
you have severe active infections, poorly controlled diabetes, or recent heart problems like a heart attack in the past year

What participation looks like

If you join this trial, you will be randomly assigned to one of two groups: one group receives standard chemotherapy and radiation, while the other group receives the same treatment plus the new immune-boosting medication. After completing this treatment over several weeks, you will undergo surgery to remove the affected portion of your esophagus. Throughout the trial, you'll have regular doctor visits, blood tests, and imaging scans to monitor your health and how well the treatment is working.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai Zhongshan Hospital, Shanghai